Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
Defining how epidermal growth factor receptor (EGFR)-targeting therapies influence the immune response is essential to increase their clinical efficacy. A growing emphasis is being placed on immune regulator genes that govern tumor – T cell interactions. Previous studies showed an increase in HLA cl...
Main Authors: | Greta Garrido, Ailem Rabasa, Cristina Garrido, Lisset Chao, Federico Garrido, Ángel M. García-Lora, Belinda Sánchez-Ramírez |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00595/full |
Similar Items
-
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
by: Tania Crombet, et al.
Published: (2011-04-01) -
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
by: Tania Crombet Ramos, et al.
Published: (2020-05-01) -
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
by: Zhao Lei, et al.
Published: (2012-12-01) -
Preparation of (177Lu-DOTA)n-PAMAM-[Nimotuzumab-F(ab’)2] as a Therapeutic Radioimmunoconjugate for EGFR Overexpressed Cancer Treatment
by: Titis Sekar Humani, et al.
Published: (2017-12-01) -
Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer
by: Chen W, et al.
Published: (2019-09-01)